盐酸吡格列酮(Pioglitazone Hydrochloride) - 药物靶点：PPARγ_在研适应症：2型糖尿病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

(±)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione、5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione、pioglitazone

+ [32]

靶点

PPARγ

作用机制

PPARγ激动剂(过氧化物酶体增长因子活化受体γ激动剂)

治疗领域

内分泌与代谢疾病

在研适应症

2型糖尿病

非在研适应症

阿尔茨海默症心血管疾病冠心病+ [14]

原研机构

Takeda Pharmaceutical Co., Ltd.

在研机构

Takeda Pharmaceuticals U.S.A., Inc.

CHEPLAPHARM Arzneimittel GmbHActavis Group PTC ehf

+ [3]

非在研机构

Vaia S.A.

复旦大学Takeda Pharma A/S

+ [4]

最高研发阶段批准上市

首次获批日期

美国 (1999-07-15),

2型糖尿病

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、孤儿药 (欧盟)

登录后查看首次获批时间轴

结构

分子式C19H21ClN2O3S

InChIKeyGHUUBYQTCDQWRA-UHFFFAOYSA-N

CAS号112529-15-4

关联

471

项与盐酸吡格列酮相关的临床试验

NCT06246799 / Not yet recruiting临床3期IIT

Comparative Effectiveness of Two Initial Combination Therapies in Patients With New Onset Diabetes

The goal of this randomized, open labelled clinical trial is to examine the efficacy, durability, and mechanism of HbA1c reduction produced by the combination of pioglitazone plus tirzepatide versus metformin plus sitagliptin in recently diagnosed type 2 diabetes mellitus patients.
The main question[s] it aims to answer are:
How effective is the combination of pioglitazone plus tirzepatide in managing blood sugar levels in people with type 2 diabetes? How does this combination compare to the use of metformin plus sitagliptin in controlling blood sugar levels? Participants will receive Pioglitazone beginning at 15 mg daily and ending 45 mg daily. (15mg month 1, 30mg month 2 and 45mg at month 3 onwards)

开始日期2024-07-01

申办/合作机构

University of Texas Health Science Center At San Antonio

[+1]

NCT06336798 / Not yet recruiting临床2期IIT

Effect of Pioglitazone on Mitochondrial Metabolism in Pulmonary Hypertension Due to Chronic Lung Disease

The goal of this clinical trial is to learn about the safety and efficacy of Pioglitazone in people with Pulmonary Hypertension (PH) due to Chronic Lung Disease (CLD). The main question it aims to answer is:
• Whether pioglitazone affects mitochondrial oxygen utilization in patients with PH due to CLD.
Participants will be asked to take pioglitazone or placebo once daily for 28 days followed by a washout period of 2 weeks followed by 28 days of the other study drug (participants randomized to placebo followed by pioglitazone or pioglitazone followed by placebo).

开始日期2024-05-01

申办/合作机构

Emory University

[+1]

NCT05727761 / Not yet recruiting临床2期IIT

Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia

This is a Phase IIa oral cavity leukoplakia study of pioglitazone 15mg and metformin 500mg BID for 12 weeks. The primary objective is to determine the clinical and histologic changes of leukoplakia from baseline following a 12 week course of twice daily pioglitazone-metformin. Outcomes are defined as are a reduction of the leukoplakia grade in > 50% of treated participants and a partial or complete clinical response defined as 50% or greater reduction in the sum of measured targeted lesions. In addition, participants who show clinical and histologic improvement should correlate with a significant reduction of Ki-67 proliferative indices in lesions of these participants as compared to baseline.

开始日期2024-03-15

申办/合作机构

University of Minnesota

100 项与盐酸吡格列酮相关的临床结果

登录后查看更多信息

100 项与盐酸吡格列酮相关的转化医学

登录后查看更多信息

100 项与盐酸吡格列酮相关的专利（医药）

登录后查看更多信息

6,050

项与盐酸吡格列酮相关的文献（医药）

2024-03-01·Research in Veterinary Science

The effect of peroxisome proliferator-activated receptor gamma (PPARγ) as a mediator of dietary fatty acids and thiazolidinedione in pulmonary arterial hypertension induced by cold stress of broilers

Article

作者: Masoudi, Ali Akbar ; Grimes, Jesse L ; Rahimi, Mahsa ; Sharafi, Mohsen ; Rahimi, Shaban ; Karimi Torshizi, Mohammad Amir

The objective of this experiment was to evaluate the effects of dietary fish oil and pioglitazone as peroxisome proliferators-activated receptor gamma (PPARγ) activating ligands on the reduction of cold-induced ascites in broiler chickens. A total of 480 one-day-old (Ross 308) male chicks were randomly allocated to four treatment groups with eight replicates of 15 birds each. The following treatments were used: 1) ambient temperature (negative control), with basal diet; 2) cold-induced ascites (positive control), with basal diet; 3) cold-induced ascites, with basal diet +10 mg/kg/day pioglitazone and 4) cold-induced ascites, with basal diet +1% of fish oil. When compared with the positive control, body weight gain was higher (P ≤ 0.05) for broilers fed diets containing fish oil and pioglitazone at 28, 42, and 0-42 d. Broilers under cold-induced ascites had the highest blood pressure at 21 and 42 d, while fish oil and pioglitazone treatment reduced the blood pressure (P ≤ 0.05). Red blood cells, white blood cells, hematocrit, erythrocyte osmotic fragility, bursa of Fabricius and spleen weights were improved (P ≤ 0.05) for chickens fed fish oil diets and pioglitazone compared to the cold-induced ascites (positive control). Exposure to cold temperature resulted in an increase in plasma T₃ and T₃/T₄ ratio and decline in plasma T₄ (P ≤ 0.05). In conclusion, PPARγ agonist pioglitazone and fish oil as source of omega-3 polyunsaturated fatty acid could be used as a strategy to reduce the negative effects of pulmonary arterial hypertension and ascites in broiler chickens.

2024-03-01·Molecular and Cellular Endocrinology

Canagliflozin improves fatty acid oxidation and ferroptosis of renal tubular epithelial cells via FOXA1-CPT1A axis in diabetic kidney disease

Article

作者: Wang, Qingzhu ; Fan, Xunjie ; Wang, Shanshan ; Song, Yi ; Chen, Duo ; Gan, Tian ; Shao, Mingwei ; Zhang, Wei ; Guo, Feng ; Qin, Guijun ; Luo, Yuanyuan ; Wei, Fangyi ; Zhao, Yanyan

Impaired fatty acid oxidation (FAO) is a metabolic hallmark of renal tubular epithelial cells (RTECs) under diabetic conditions. Disturbed FAO may promote cellular oxidative stress and insufficient energy production, leading to ferroptosis subsequently. Canagliflozin, an effective anti-hyperglycemic drug, may exert potential reno-protective effects by upregulating FAO and inhibiting ferroptosis in RTECs. However, the mechanisms involved remain unclear. The present study is aimed to characterize the detailed mechanisms underlying the impact of canagliflozin on FAO and ferroptosis. Type 2 diabetic db/db mice were administrated daily by gavage with canagliflozin (20 mg/kg/day, 40 mg/kg/day) or positive control drug pioglitazone (10 mg/kg/day) for 12 weeks. The results showed canagliflozin effectively improved renal function and structure, reduced lipid droplet accumulation, enhanced FAO with increased ATP contents and CPT1A expression, a rate-limiting enzyme of FAO, and relieved ferroptosis in diabetic mice. Moreover, overexpression of FOXA1, a transcription factor related with lipid metabolism, was observed to upregulate the level of CPT1A, and further alleviated ferroptosis in high glucose cultured HK-2 cells. Whereas FOXA1 knockdown had the opposite effect. Mechanistically, chromatin immunoprecipitation assay and dual-luciferase reporter gene assay results demonstrated that FOXA1 transcriptionally promoted the expression of CPT1A through a sis-inducible element located in the promoter region of the protein. In conclusion, these data suggest that canagliflozin improves FAO and attenuates ferroptosis of RTECs via FOXA1-CPT1A axis in diabetic kidney disease.

2024-03-01·Naunyn-Schmiedeberg's Archives of Pharmacology

Peroxisome proliferator activated receptor-gamma (PPAR-γ) ligand, pioglitazone, increases analgesic and anti-inflammatory effects of naproxen

Article

作者: Cheraghi-Poor, Mohammad ; Haddadi, Rasool

The aim of this study was the investigation of analgesic and anti-inflammatory activity of naproxen and pioglitazone following intra-plantar injection of carrageenan and assessment of the PPAR-γ receptor involvement in these effects. Rats were intra-plantarly injected with carrageenan (1%, 100 μl) to induce thermal hyperalgesia and paw inflammation. Different groups of rats were pre-treated intraperitoneally with naproxen (1 and 10 mg/kg) or pioglitazone (3 and 10 mg/kg) or GW9662 (a selective PPAR-γ antagonist, 100 μl/paw). The volume of the paw was evaluated using a plethysmometer, and the hot plate test was employed to assess the pain threshold in the animals. Finally, TNF-α, IL-1ß, IL-6, and myeloperoxidase (MPO) activity status were evaluated in the hind paw tissue. Naproxen and pioglitazone demonstrated analgesic and anti-inflammatory activity. Concurrent injection of an ineffective dose of naproxen (1 mg/kg) with an ineffective dose of pioglitazone (3 mg/kg) caused augmented analgesic and anti-inflammatory activity, significantly (p≤0.001 and p≤0.01, respectively). Additionally, intra-plantar injection of GW-9662 before naproxen or pioglitazone significantly suppressed their analgesic (p≤0.001) and anti-inflammatory activity (p≤0.01). Also, naproxen and pioglitazone (10 mg/kg) significantly (p≤0.001) reduced carrageenan-induced MPO activity and TNF-α, IL-6, and IL-1ß releasing. Furthermore, PPAR-γ blockade significantly prevented suppressive effects of naproxen and pioglitazone on the MPO activity and inflammatory cytokines. Pioglitazone significantly increased analgesic and anti-inflammatory effects of naproxen. This study proposes that concurrent treatment with naproxen and pioglitazone may be a substitute for overcome pain and inflammation clinically, in the future, particularly in patients with cardiovascular disorders and diabetes.

86

项与盐酸吡格列酮相关的新闻（医药）

2024-02-26

·药智网

斥资31亿，华润最新动作

0131.15亿元华润双鹤拿下“毓婷”等知名产品近日，华润双鹤发布公告，以31.15亿元收购北京医药集团持有的华润紫竹药业100%股权，收购价较华润紫竹单体财务报表净资产账面价值11.52亿元的增值率为170.4%。华润紫竹为北药集团的全资子公司，其实际控制人为华润集团，此次收购实际上是华润集团化药板块业务整合的举措之一。华润紫竹主要从事女性健康用药及器械、口腔用药、眼科用药、糖尿病用药、原料药研发生产销售业务，主营生殖健康类药物包括左炔诺孕酮片“毓婷”“金毓婷”等。“毓婷”是原国家计生委与华润紫竹共同研发的中国首个非处方紧急避孕药，自1998年上市后，持续在全国市场占有率保持第一。华润双鹤隶属于华润集团，定位为化学药平台支柱性企业，主营业务涵盖新药研发、制剂生产、药品销售、原料药生产及制药装备等方面，布局普仿药业务、输液业务、差异化药业务和创新药业务四大业务平台。其最新季度财报显示，截至2023年第三季度，华润双鹤总营收约75.46亿元，同比上涨5.42%；归属于上市公司股东的净利润10.78亿元，同比增长10.12%。截至报告期末，华润双鹤总资产约150.47亿元。华润双鹤表示，通过收购华润紫竹，可以丰富华润双鹤女性健康用药、眼科制剂、口腔类药物产品组合，丰富华润双鹤在专科领域的产品线。目前，华润双鹤的降压、降糖、脑血管、降脂等慢病业务占比达到三成，具体产品包括复方利血平氨苯蝶啶片（0号）、格列喹酮片（糖适平）、苯磺酸氨氯地平片（压氏达）等，随着国采常态化推进，慢病业务是其受影响最大的业务领域。相应的，其专科业务是以临床价值明确、短期内未受带量采购影响的差异化产品为主，华润双鹤表示该业务将作为其中长期发展的重要引擎，覆盖儿科、肾科、精神/神经、抗凝和麻醉镇痛等领域。华润双鹤在对此次收购增值的评估详述中提到，随着仿制药一致性评价等工作开展，我国仿制药质量将得到全面提高，在临床上实现与原研药的相互替代，一致性评价对原料药质量提出更高要求，同时在仿制药进入螺旋降价趋势的大环境下，我国仿制药行业在优胜劣汰中迎来洗牌。因此，真正具有技术研发实力的公司将脱颖而出，具备原料药产能的药企有利于保障产品质量、控制生产成本，提升综合盈利水平。除了通过收购华润紫竹进入女性健康领域外，华润双鹤还计划积极与企业进行相关产品合作，将儿科领域扩展到大儿科，形成“女性健康+儿科”的专科产品序列。02加强现有领域优势、快速入局新领域“华润系”收购不断此次收购距离华润双鹤的上一起大型收购过去不到半年。去年9月末，华润双鹤发布公告以2.6亿元收购贵州天安药业89.681%股权，天安药业旗下拥有“安多可”盐酸二甲双胍肠溶片、“安多明”羟苯磺酸钙胶囊、“安多美”格列美脲片、“安多健”盐酸吡格列酮分散片等多款口服降糖药品。由于慢病用药领域集采覆盖面广、竞争品牌多，集采续约过程中部分省区独家中选可能会变成多家中选，华润双鹤曾在其半年报中表示将加强产品组合，布局其他治疗领域等。收购天安药业股权有助于华润双鹤进一步丰富其糖尿病药物产品管线，增强其在糖尿病领域的市场地位，提升盈利能力和综合竞争力。再加上此前对神舟生物、天东制药的收购，华润双鹤进入生物发酵领域、加强肝素抗凝领域布局，其非输液板块管线得到进一步丰富。不止是华润双鹤，近年来，“华润系”通过收并购补充管线布局的动作不断。今年年初，华润三九对润生药业进行投资，并取得润生药业丙酸氟替卡松吸入粉雾剂产品上市后在中国大陆地区的独家经销及推广权利一揽子交易。此次交易可以视作华润三九对高端吸入制剂的布局。据悉，润生药业专注于呼吸用药产品研发、生产，服务于哮喘和慢性阻塞性肺疾病患者，首个核心产品沙美特罗替卡松粉吸入剂是GSK的Advair®Diskus®的高端仿制药。交易全部完成后，华润三九将成为润生药业的第一大股东，拥有其23.5689%的股权，这一方面丰富了华润三九的呼吸系统用药，提升其呼吸系统领域专业形象；另一方面也有望为其后续新品开发提供助力。华润医药官网显示，其大健康板块共有六大公司，除华润双鹤、华润三九外，还包括华润医药集团、华润医药商业集团、华润江中、华润健康集团。对体量较大、资金相对充足的企业而言，适时展开收并购不失为巩固现有领域优势、快速入局新领域的高效手段。注：以上图片来源赛柏蓝来源 | 赛柏蓝（药智网获取授权转载）撰稿 | 陈芋责任编辑 | 八角声明：本文系药智网转载内容，图片、文字版权归原作者所有，转载目的在于传递更多信息，并不代表本平台观点。如涉及作品内容、版权和其它问题，请在本平台留言，我们将在第一时间删除。商务合作 | 王存星 19922864877（同微信）阅读原文，是受欢迎的文章哦

一致性评价并购财报带量采购

2024-02-25

·赛柏蓝

斥资31亿，华润系最新动作

作者 | 陈芋来源 | 赛柏蓝 0131.15亿元华润双鹤拿下“毓婷”等知名产品 2月24日，华润双鹤发布公告，以31.15亿元收购北京医药集团持有的华润紫竹药业100%股权，收购价较华润紫竹单体财务报表净资产账面价值11.52亿元的增值率为170.4%。华润紫竹为北药集团的全资子公司，其实际控制人为华润集团，此次收购实际上是华润集团化药板块业务整合的举措之一。华润紫竹主要从事女性健康用药及器械、口腔用药、眼科用药、糖尿病用药、原料药研发生产销售业务，主营生殖健康类药物包括左炔诺孕酮片“毓婷”“金毓婷”等。 “毓婷”是原国家计生委与华润紫竹共同研发的中国首个非处方紧急避孕药，自1998年上市后，持续在全国市场占有率保持第一。华润双鹤隶属于华润集团，定位为化学药平台支柱性企业，主营业务涵盖新药研发、制剂生产、药品销售、原料药生产及制药装备等方面，布局普仿药业务、输液业务、差异化药业务和创新药业务四大业务平台。其最新季度财报显示，截至2023年第三季度，华润双鹤总营收约75.46亿元，同比上涨5.42%；归属于上市公司股东的净利润10.78亿元，同比增长10.12%。截至报告期末，华润双鹤总资产约150.47亿元。华润双鹤表示，通过收购华润紫竹，可以丰富华润双鹤女性健康用药、眼科制剂、口腔类药物产品组合，丰富华润双鹤在专科领域的产品线。目前，华润双鹤的降压、降糖、脑血管、降脂等慢病业务占比达到三成，具体产品包括复方利血平氨苯蝶啶片（0 号）、格列喹酮片（糖适平）、苯磺酸氨氯地平片（压氏达）等，随着国采常态化推进，慢病业务是其受影响最大的业务领域。相应的，其专科业务是以临床价值明确、短期内未受带量采购影响的差异化产品为主，华润双鹤表示该业务将作为其中长期发展的重要引擎，覆盖儿科、肾科、精神/神经、抗凝和麻醉镇痛等领域。华润双鹤在对此次收购增值的评估详述中提到，随着仿制药一致性评价等工作开展，我国仿制药质量将得到全面提高，在临床上实现与原研药的相互替代，一致性评价对原料药质量提出更高要求，同时在仿制药进入螺旋降价趋势的大环境下，我国仿制药行业在优胜劣汰中迎来洗牌。因此，真正具有技术研发实力的公司将脱颖而出，具备原料药产能的药企有利于保障产品质量、控制生产成本，提升综合盈利水平。除了通过收购华润紫竹进入女性健康领域外，华润双鹤还计划积极与企业进行相关产品合作，将儿科领域扩展到大儿科，形成“女性健康+儿科”的专科产品序列。02加强现有领域优势、快速入局新领域“华润系”收购不断此次收购距离华润双鹤的上一起大型收购过去不到半年。去年9月末，华润双鹤发布公告以2.6亿元收购贵州天安药业89.681%股权，天安药业旗下拥有“安多可”盐酸二甲双胍肠溶片、“安多明”羟苯磺酸钙胶囊、“安多美”格列美脲片、“安多健”盐酸吡格列酮分散片等多款口服降糖药品。由于慢病用药领域集采覆盖面广、竞争品牌多，集采续约过程中部分省区独家中选可能会变成多家中选，华润双鹤曾在其半年报中表示将加强产品组合，布局其他治疗领域等。收购天安药业股权有助于华润双鹤进一步丰富其糖尿病药物产品管线，增强其在糖尿病领域的市场地位，提升盈利能力和综合竞争力。再加上此前对神舟生物、天东制药的收购，华润双鹤进入生物发酵领域、加强肝素抗凝领域布局，其非输液板块管线得到进一步丰富。不止是华润双鹤，近年来，“华润系”通过收并购补充管线布局的动作不断。今年年初，华润三九对润生药业进行投资，并取得润生药业丙酸氟替卡松吸入粉雾剂产品上市后在中国大陆地区的独家经销及推广权利一揽子交易。此次交易可以视作华润三九对高端吸入制剂的布局。据悉，润生药业专注于呼吸用药产品研发、生产，服务于哮喘和慢性阻塞性肺疾病患者，首个核心产品沙美特罗替卡松粉吸入剂是GSK的Advair® Diskus®的高端仿制药。交易全部完成后，华润三九将成为润生药业的第一大股东，拥有其23.5689%的股权，这一方面丰富了华润三九的呼吸系统用药，提升其呼吸系统领域专业形象；另一方面也有望为其后续新品开发提供助力。华润医药官网显示，其大健康板块共有六大公司，除华润双鹤、华润三九外，还包括华润医药集团、华润医药商业集团、华润江中、华润健康集团。对体量较大、资金相对充足的企业而言，适时展开收并购不失为巩固现有领域优势、快速入局新领域的高效手段。 END内容沟通：13810174402医药代表交流群扫描下方二维码加入银发经济市场机遇交流群扫描下方二维码加入左下角「关注账号」，右下角「在看」，防止失联

一致性评价并购带量采购财报

2024-01-25

·蒲公英Ouryao

63家药企被点名通报→

转自：青海省医疗保障局编辑：水晶2024年1月22日，青海省医疗保障局办公室发布了《关于全省公立医疗机构第四季度药品配送情况的通报》，对全省连续3个月配送率低于80%的药品的生产企业进行详细通报。涉及药企63家，品种70个。而其中连续3个月配送率为0的药品数量达到50个。青海省医疗保障局要求，连续3个月配送率低于80%的67个药品的生产企业要详细了解未及时配送的原因，并于1月31日前向青海省医保局价格招采处书面报送整改措施（若由于配送企业未及时配送造成连续3个月配送率低于80%的，生产企业可向青海省医疗保障局申请修改配送关系）。 2024年1月22日，青海省医疗保障局办公室发布了《关于全省公立医疗机构第四季度药品配送情况的通报》，对全省药品配送情况和配送企业配送情况，尤其是连续3个月配送率低于80%的药品的生产企业进行详细通报。药品配送情况配送企业配送情况根据数据可以看出，在药品层面，青海省第四季度的总配送率接近90%，配送率不到80%的药品约占12%，数量达到1945个。连续3个月配送率不到80%的药品数量达到70个；而连续3个月配送率为0的药品数量达到50个（详细数据见文末）。连续3个月配送率为0的药品：人胰岛素注射液、注射用硼替佐米、非诺贝特胶囊、格列齐特缓释片、复方黄柏液涂剂(复方黄柏液) 、疏肝益阳胶囊、血府逐瘀丸、风湿骨痛片、小儿柴桂退热口服液、螺内酯片、金黄利胆胶囊、脂肪乳注射液(C14-24) 、风湿骨痛胶囊、银翘解毒颗粒、七味胃痛胶囊、补心气口服液、左卡尼汀口服溶液、依折麦布片、二甲双胍格列吡嗪片、甲硝唑片、盐酸氨溴索注射液、盐酸吡格列酮片、尼可刹米注射液、螺内酯片、阿奇霉素颗粒、酚磺乙胺注射液、小儿宝泰康颗粒、替硝唑氯化钠注射液、柴胡注射液、人工牛黄甲硝唑胶囊、马来酸氯苯那敏片、启脾丸、黄连上清丸、八珍益母丸、格列吡嗪片、甲钴胺片、双嘧达莫片、盐酸布比卡因注射液、风湿骨痛胶囊、人血白蛋白、盐酸西替利嗪口服溶液、硝苯地平控释片、口炎清颗粒、注射用炎琥宁、小儿肺咳颗粒、醋氯芬酸片、抗病毒颗粒、蜜炼川贝枇杷膏、小儿咳喘灵口服液、复方氨酚烷胺胶囊。整改措施：青海省医疗保障局要求，连续3个月配送率低于80%的67个药品的生产企业要详细了解未及时配送的原因，并于1月31日前向青海省医保局价格招采处书面报送整改措施（若由于配送企业未及时配送造成连续3个月配送率低于80%的，生产企业可向青海省医疗保障局申请修改配送关系）。其中，连续3个月配送率低于80%的青海中惠药业有限公司被青海省取消配送资格。欢迎留言，更多观点。2023年精彩文章推荐:推荐阅读：蒲公英Ouryao视频号投稿、广告、商务合作： Qinrenlvcha

申请上市

100 项与盐酸吡格列酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00945	盐酸吡格列酮	A10BG03	DB01132

研发状态

适应症	最高研发状态	国家/地区	公司
2型糖尿病	批准上市	冰岛更多	Accord Healthcare SLU 更多
阿尔茨海默症	终止	美国更多	Takeda Pharmaceutical Co., Ltd. 更多
轻度认知障碍	终止	英国更多	Takeda Pharmaceutical Co., Ltd. 更多
冠心病	无进展	德国更多	Takeda Pharmaceutical Co., Ltd. 更多
糖尿病	无进展	丹麦更多	Takeda Pharmaceutical Co., Ltd. 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ISRCTN11062950;ISRCTN29234515;ISRCTN45546616 (Pubmed)	N/A	多囊卵巢综合征 HOTAIR rs1443512 genotype	65	pioglitazone	簾糧蓋鑰醖餘艱願範網(積範衊廠夢遞繭蓋鏇鑰) = 繭廠膚糧簾繭壓製蓋鬱網構鏇膚廠齋淵繭鹹壓 (簾壓醖願齋醖簾觸鏇膚 ) 更多	-	2024-04-01
NCT00843791 (CTgov)	N/A	胰岛素抵抗 \| 肥胖	6	placebo	齋願積繭鏇膚襯淵網艱(廠製醖壓遞繭鑰糧繭鹹) = 窪選夢簾壓憲蓋鑰築齋窪觸醖製願鹽願憲網顧 (憲繭築鹽襯蓋廠窪憲簾, 獵積壓鏇繭鬱襯衊範齋 ~ 鑰構鏇壓夢觸夢觸膚繭) 更多	-	2023-01-30
NCT04123067 (CTgov)	临床1/2期	糖尿病 \| 高血糖 \| 急性缺血性卒中	1	Pioglitazone 45 mg (Pioglitazone Treatment Group)	膚衊壓顧遞製鏇顧積願(網積願鑰夢鏇構淵獵艱) = 範範簾襯選鏇淵遞餘蓋齋製廠製蓋網夢範壓衊 (窪選鑰蓋鏇願鏇夢願顧, 衊淵鬱鬱願憲襯蓋獵艱 ~ 鬱衊襯齋顧蓋鑰醖鬱餘) 更多	-	2022-09-15
				Placebo oral tablet (Placebo Group)	膚衊壓顧遞製鏇顧積願(網積願鑰夢鏇構淵獵艱) = 顧鹽壓觸繭繭繭簾範鑰齋製廠製蓋網夢範壓衊 (窪選鑰蓋鏇願鏇夢願顧, 壓襯衊鏇獵築淵鑰簾壓 ~ 蓋獵繭餘鹽鏇獵築鹽獵) 更多
NCT03011775 (CTgov)	临床4期	胰岛素抵抗 \| 冠心病 \| 代谢综合征 ... 更多	43	Rosuvastatin Calcium 20 MG Oral Tablet+Bisoprolol Fumarate 2.5 MG Oral Tablet+Ramipril 5 MG+Isosorbide Dinitrate 10Mg Tablet+Pioglitazone 15 mg Tablet+Acetylsalicylic Acid 75Mg Tablet (Pioglitazone + Standard Care)	艱艱夢製願糧鏇蓋鏇窪(積糧網膚鏇簾鬱鹽餘餘) = 鑰窪齋蓋醖鏇艱構網壓範鬱構獵積艱積願餘糧 (觸製鹹鏇鑰窪選艱構網, 獵艱觸獵獵積簾淵繭範 ~ 觸範壓壓憲觸獵憲蓋選) 更多	-	2022-03-10
				Rosuvastatin Calcium 20 MG Oral Tablet+Bisoprolol Fumarate 2.5 MG Oral Tablet+Ramipril 5 MG+Isosorbide Dinitrate 10Mg Tablet+Acetylsalicylic Acid 75Mg Tablet (Standard Care)	艱艱夢製願糧鏇蓋鏇窪(積糧網膚鏇簾鬱鹽餘餘) = 餘醖鏇遞廠鑰壓鬱鹹鹹範鬱構獵積艱積願餘糧 (觸製鹹鏇鑰窪選艱構網, 鹽窪膚鹹廠膚築壓窪衊 ~ 範襯艱選鹽選網願簾襯) 更多
NCT02338999 (CTgov)	临床1/2期	系统性红斑狼疮	88	Placebo+Pioglitazone (Pioglitazone, Then Placebo)	製鹽醖蓋醖膚獵構襯遞(構壓夢衊選製衊鹽簾壓) = 夢壓憲蓋廠艱醖壓艱獵範淵積蓋餘鬱鹹壓獵醖 (簾構鹽網範網窪鑰顧網, 鹽鬱網鬱願鹽襯糧觸鏇 ~ 觸醖淵餘餘憲鑰衊醖製) 更多	-	2021-09-14
				Placebo+Pioglitazone (Placebo, Then Pioglitazone)	製鹽醖蓋醖膚獵構襯遞(構壓夢衊選製衊鹽簾壓) = 衊鑰製衊網範築獵顧構範淵積蓋餘鬱鹹壓獵醖 (簾構鹽網範網窪鑰顧網, 積製衊膚膚膚糧壓製網 ~ 願製蓋艱獵壓積淵遞廠) 更多
NCT01135394 (CTgov)	N/A	2型糖尿病	114	Pioglitazone	製鏇窪壓築艱淵廠糧願(醖鹽衊夢遞繭醖齋衊願) = 鏇簾築獵膚壓膚壓壓壓艱鏇窪夢糧窪築餘蓋選 (淵範壓艱製淵遞餘構齋, 夢壓鏇憲夢遞願遞鹽製 ~ 積網糧淵遞襯鏇壓製顧) 更多	-	2021-05-18
NCT01748994 (CTgov)	N/A	肥胖 \| 代谢综合征	63	Placebo (Placebo)	繭鬱繭遞遞窪觸鹹憲淵(鏇鏇顧蓋憲鬱製構壓繭) = 觸糧窪窪範鹹製餘鑰衊遞選齋醖醖顧壓襯積積 (製衊醖鏇選製觸餘淵廠, 願簾窪淵壓觸鬱窪鏇選 ~ 鑰積製網淵繭網糧淵鏇) 更多	-	2021-04-30
				Pioglitazone (Drug)	繭鬱繭遞遞窪觸鹹憲淵(鏇鏇顧蓋憲鬱製構壓繭) = 積鹽遞鹹積衊鹹廠衊衊遞選齋醖醖顧壓襯積積 (製衊醖鏇選製觸餘淵廠, 襯蓋鏇築廠範鹹遞鑰範 ~ 壓網鏇繭選鹹鹽構衊鹽) 更多
NCT01838317 (CTgov)	临床2期	胰腺癌	14	Pioglitazone (Pioglitazone and Chemotherapy Without Diabetes)	醖獵餘鹽鏇繭範構鬱壓(繭獵壓鬱製夢築鬱窪鏇) = 衊簾淵餘範衊獵壓製鹽餘獵築簾顧膚觸選艱顧 (觸鹹衊範窪獵鹽鹹願觸, 積膚艱繭壓繭鏇製積築 ~ 鹽簾憲餘鹽願觸鬱鹹鑰) 更多	-	2021-03-01
				Pioglitazone (Pioglitazone and Chemotherapy - With Diabetes)	醖獵餘鹽鏇繭範構鬱壓(繭獵壓鬱製夢築鬱窪鏇) = 繭網簾鏇憲選願積艱襯餘獵築簾顧膚觸選艱顧 (觸鹹衊範窪獵鹽鹹願觸, 襯艱製積憲鹽簾網鏇齋 ~ 遞襯鹽鬱醖餘鏇衊鹽積) 更多
NCT02697617 (PIOPKD, Pubmed) 人工标引	临床1期	常染色体显性多囊肾病	18	pioglitazone	壓鹽選艱艱鏇壓鏇鹽膚(夢範醖鏇鑰繭範獵窪製): difference = 0.16 (95% CI, 0.24 ~ 2.96), P-Value = 0.024 更多	积极	2021-01-26
				Placebo
NCT03860753 (CTgov)	临床1/2期	酒精使用障碍 \| 酗酒	4	Pioglitazone (Pioglitazone)	醖壓網鹹壓積廠顧構襯(艱積糧蓋襯鏇築艱願構) = 憲壓襯夢醖繭鏇觸遞醖簾襯選廠願鑰鑰簾鬱廠 (構鹹艱鹽壓築範壓窪衊, 鏇鹽網壓餘蓋積鏇願窪 ~ 壓壓齋憲鏇鏇鹽鑰觸鬱) 更多	-	2020-10-26
				Placebo (Placebo)	簾餘製夢憲選膚簾獵鑰(蓋壓選鑰憲築齋糧積築) = 繭築蓋築網願淵糧繭壓選獵鑰壓選壓鬱憲壓鏇 (繭艱艱憲壓鬱鹽糧遞糧, 憲鏇餘憲築範鑰築餘壓 ~ 膚觸窪遞遞選膚獵襯選) 更多